February 11, 2023

We celebrated the women's power in science

The movement adopted by the United Nations General Assembly promotes women’s full access and equal participation in Science, Technology, Engineering, and Mathematics (STEM) fields.

Surveys confirm that only 33% of researchers are women, awarded less funding than men, and less likely to be promoted. This day is a reminder of women’s significant contribution to science and the importance of strengthening it worldwide.

We are proud to say that our scientific team in MultiplexDX consists of more women than men, and they all share the same passion for science and research.

Source: unwomen.org

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News